114 related articles for article (PubMed ID: 35292724)
1. A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.
Brown LC; Halabi S; Somarelli JA; Humeniuk M; Wu Y; Oyekunle T; Howard L; Huang J; Anand M; Davies C; Patel P; Staats J; Weinhold KJ; Harrison MR; Zhang T; George DJ; Armstrong AJ
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):762-769. PubMed ID: 35292724
[TBL] [Abstract][Full Text] [Related]
2. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
Kwan EM; Spain L; Anton A; Gan CL; Garrett L; Chang D; Liow E; Bennett C; Zheng T; Yu J; Dai C; Du P; Jia S; Fettke H; Abou-Seif C; Kothari G; Shaw M; Parente P; Pezaro C; Tran B; Siva S; Azad AA
Eur Urol; 2022 Mar; 81(3):253-262. PubMed ID: 34493414
[TBL] [Abstract][Full Text] [Related]
3. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.
Chan DL; Rodriguez-Freixinos V; Doherty M; Wasson K; Iscoe N; Raskin W; Hallet J; Myrehaug S; Law C; Thawer A; Nguyen K; Singh S
Eur J Cancer; 2022 Jul; 169():74-81. PubMed ID: 35504244
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract][Full Text] [Related]
5. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.
Li H; Sahu KK; Brundage J; Benson M; Swami U; Boucher KM; Gupta S; Hawks J; Sirohi D; Agarwal N; Maughan BL
Oncologist; 2023 Aug; 28(8):737-e693. PubMed ID: 36952231
[TBL] [Abstract][Full Text] [Related]
7. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
Beltran H; Oromendia C; Danila DC; Montgomery B; Hoimes C; Szmulewitz RZ; Vaishampayan U; Armstrong AJ; Stein M; Pinski J; Mosquera JM; Sailer V; Bareja R; Romanel A; Gumpeni N; Sboner A; Dardenne E; Puca L; Prandi D; Rubin MA; Scher HI; Rickman DS; Demichelis F; Nanus DM; Ballman KV; Tagawa ST
Clin Cancer Res; 2019 Jan; 25(1):43-51. PubMed ID: 30232224
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
[TBL] [Abstract][Full Text] [Related]
11. Case Series of Men with the Germline APC I1307K variant and Treatment-Emergent Neuroendocrine Prostate Cancer.
Economides MP; Nakazawa M; Lee JW; Li X; Hollifield L; Chambers R; Sarfaty M; Goldberg JD; Antonarakis ES; Wise DR
Clin Genitourin Cancer; 2024 Feb; 22(1):e31-e37.e1. PubMed ID: 37482523
[TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib.
Lee DW; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH; Kim TY; Han SW; Oh DY; Im SA; Kim TY; Lee Y; Kim H; Lee KH
Clin Cancer Res; 2021 Feb; 27(3):713-718. PubMed ID: 33139266
[TBL] [Abstract][Full Text] [Related]
13. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
[TBL] [Abstract][Full Text] [Related]
14. Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE.
Gassian N; Frontczak A; Mouillet G; Vernerey D; Manseur O; Goujon M; Meurisse A; Berthod D; Robert E; Calcagno F; Thiery-Vuillemin A
Bull Cancer; 2020 Jun; 107(5S):eS16-eS21. PubMed ID: 32620211
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.
Eule CJ; Hu J; Al-Saad S; Collier K; Boland P; Lewis AR; McKay RR; Narayan V; Bosse D; Mortazavi A; Rose TL; Costello BA; Bryce AH; Lam ET
Clin Genitourin Cancer; 2023 Aug; 21(4):483-490. PubMed ID: 37193610
[TBL] [Abstract][Full Text] [Related]
16. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
[TBL] [Abstract][Full Text] [Related]
17. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
[TBL] [Abstract][Full Text] [Related]
18. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
Barlesi F; Vansteenkiste J; Spigel D; Ishii H; Garassino M; de Marinis F; Özgüroğlu M; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Ellers-Lenz B; Bajars M; Ruisi M; Park K
Lancet Oncol; 2018 Nov; 19(11):1468-1479. PubMed ID: 30262187
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]